Premenstrual dysphoric disorder

B. L. Parry, Sara Nowakowski, L. F. Martinez, S. L. Berga

Research output: Chapter in Book/Report/Conference proceedingChapter

1 Citation (Scopus)

Abstract

Premenstrual dysphoric disorder (PMDD) is defined as a depressive disorder, not otherwise specified, in the American Psychiatric Association's Diagnostic and Statistical Manual of Mental Disorders. It is characterized by mood, appetite, energy, and cognitive changes that occur during the late luteal (premenstrual) phase of the menstrual cycle and remit shortly after the onset of menses. Symptoms are severe enough to interfere with functioning at home, school, or work. It occurs in an estimated 5% of women, and if left untreated, may become more severe and extend in duration over time. Based on current evidence, serotonergic dysfunction appears to be linked with its hormonal etiology, as selective serotonin reuptake inhibitors (SSRIs) demonstrate efficacy and safety. Both fluoxetine and sertraline have been approved by the Food and Drug Administration for use in PMDD. More recent studies suggest that at least among the SSRIs with longer half-lives, such as fluoxetine, the medication can be given in the second-half (luteal phase) only to achieve beneficial effects. Once the medication is stopped, however, symptoms recur in a majority of women within a few months. Other nonpharmacological approaches to treatment, such as sleep and light therapies, are being developed based on chronobiological hypotheses.

Original languageEnglish (US)
Title of host publicationHormones, Brain and Behavior Online
PublisherElsevier Inc.
Pages2945-2974
Number of pages30
ISBN (Print)9780080887838
DOIs
StatePublished - 2010
Externally publishedYes

Fingerprint

Fluoxetine
Luteal Phase
Serotonin Uptake Inhibitors
Sertraline
Phototherapy
Menstruation
Appetite
United States Food and Drug Administration
Depressive Disorder
Diagnostic and Statistical Manual of Mental Disorders
Psychiatry
Sleep
Safety
Premenstrual Dysphoric Disorder
Therapeutics

Keywords

  • Depression
  • Luteal phase
  • Menstrual cycle
  • Mood disorders
  • Premenstrual dysphoric disorder
  • Reproductive cycle
  • Women

ASJC Scopus subject areas

  • Neuroscience(all)

Cite this

Parry, B. L., Nowakowski, S., Martinez, L. F., & Berga, S. L. (2010). Premenstrual dysphoric disorder. In Hormones, Brain and Behavior Online (pp. 2945-2974). Elsevier Inc.. https://doi.org/10.1016/B978-008088783-8.00094-2

Premenstrual dysphoric disorder. / Parry, B. L.; Nowakowski, Sara; Martinez, L. F.; Berga, S. L.

Hormones, Brain and Behavior Online. Elsevier Inc., 2010. p. 2945-2974.

Research output: Chapter in Book/Report/Conference proceedingChapter

Parry, BL, Nowakowski, S, Martinez, LF & Berga, SL 2010, Premenstrual dysphoric disorder. in Hormones, Brain and Behavior Online. Elsevier Inc., pp. 2945-2974. https://doi.org/10.1016/B978-008088783-8.00094-2
Parry BL, Nowakowski S, Martinez LF, Berga SL. Premenstrual dysphoric disorder. In Hormones, Brain and Behavior Online. Elsevier Inc. 2010. p. 2945-2974 https://doi.org/10.1016/B978-008088783-8.00094-2
Parry, B. L. ; Nowakowski, Sara ; Martinez, L. F. ; Berga, S. L. / Premenstrual dysphoric disorder. Hormones, Brain and Behavior Online. Elsevier Inc., 2010. pp. 2945-2974
@inbook{dc09fd21d83547e2a6dca8b10acb3af8,
title = "Premenstrual dysphoric disorder",
abstract = "Premenstrual dysphoric disorder (PMDD) is defined as a depressive disorder, not otherwise specified, in the American Psychiatric Association's Diagnostic and Statistical Manual of Mental Disorders. It is characterized by mood, appetite, energy, and cognitive changes that occur during the late luteal (premenstrual) phase of the menstrual cycle and remit shortly after the onset of menses. Symptoms are severe enough to interfere with functioning at home, school, or work. It occurs in an estimated 5{\%} of women, and if left untreated, may become more severe and extend in duration over time. Based on current evidence, serotonergic dysfunction appears to be linked with its hormonal etiology, as selective serotonin reuptake inhibitors (SSRIs) demonstrate efficacy and safety. Both fluoxetine and sertraline have been approved by the Food and Drug Administration for use in PMDD. More recent studies suggest that at least among the SSRIs with longer half-lives, such as fluoxetine, the medication can be given in the second-half (luteal phase) only to achieve beneficial effects. Once the medication is stopped, however, symptoms recur in a majority of women within a few months. Other nonpharmacological approaches to treatment, such as sleep and light therapies, are being developed based on chronobiological hypotheses.",
keywords = "Depression, Luteal phase, Menstrual cycle, Mood disorders, Premenstrual dysphoric disorder, Reproductive cycle, Women",
author = "Parry, {B. L.} and Sara Nowakowski and Martinez, {L. F.} and Berga, {S. L.}",
year = "2010",
doi = "10.1016/B978-008088783-8.00094-2",
language = "English (US)",
isbn = "9780080887838",
pages = "2945--2974",
booktitle = "Hormones, Brain and Behavior Online",
publisher = "Elsevier Inc.",

}

TY - CHAP

T1 - Premenstrual dysphoric disorder

AU - Parry, B. L.

AU - Nowakowski, Sara

AU - Martinez, L. F.

AU - Berga, S. L.

PY - 2010

Y1 - 2010

N2 - Premenstrual dysphoric disorder (PMDD) is defined as a depressive disorder, not otherwise specified, in the American Psychiatric Association's Diagnostic and Statistical Manual of Mental Disorders. It is characterized by mood, appetite, energy, and cognitive changes that occur during the late luteal (premenstrual) phase of the menstrual cycle and remit shortly after the onset of menses. Symptoms are severe enough to interfere with functioning at home, school, or work. It occurs in an estimated 5% of women, and if left untreated, may become more severe and extend in duration over time. Based on current evidence, serotonergic dysfunction appears to be linked with its hormonal etiology, as selective serotonin reuptake inhibitors (SSRIs) demonstrate efficacy and safety. Both fluoxetine and sertraline have been approved by the Food and Drug Administration for use in PMDD. More recent studies suggest that at least among the SSRIs with longer half-lives, such as fluoxetine, the medication can be given in the second-half (luteal phase) only to achieve beneficial effects. Once the medication is stopped, however, symptoms recur in a majority of women within a few months. Other nonpharmacological approaches to treatment, such as sleep and light therapies, are being developed based on chronobiological hypotheses.

AB - Premenstrual dysphoric disorder (PMDD) is defined as a depressive disorder, not otherwise specified, in the American Psychiatric Association's Diagnostic and Statistical Manual of Mental Disorders. It is characterized by mood, appetite, energy, and cognitive changes that occur during the late luteal (premenstrual) phase of the menstrual cycle and remit shortly after the onset of menses. Symptoms are severe enough to interfere with functioning at home, school, or work. It occurs in an estimated 5% of women, and if left untreated, may become more severe and extend in duration over time. Based on current evidence, serotonergic dysfunction appears to be linked with its hormonal etiology, as selective serotonin reuptake inhibitors (SSRIs) demonstrate efficacy and safety. Both fluoxetine and sertraline have been approved by the Food and Drug Administration for use in PMDD. More recent studies suggest that at least among the SSRIs with longer half-lives, such as fluoxetine, the medication can be given in the second-half (luteal phase) only to achieve beneficial effects. Once the medication is stopped, however, symptoms recur in a majority of women within a few months. Other nonpharmacological approaches to treatment, such as sleep and light therapies, are being developed based on chronobiological hypotheses.

KW - Depression

KW - Luteal phase

KW - Menstrual cycle

KW - Mood disorders

KW - Premenstrual dysphoric disorder

KW - Reproductive cycle

KW - Women

UR - http://www.scopus.com/inward/record.url?scp=84884736408&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84884736408&partnerID=8YFLogxK

U2 - 10.1016/B978-008088783-8.00094-2

DO - 10.1016/B978-008088783-8.00094-2

M3 - Chapter

AN - SCOPUS:84884736408

SN - 9780080887838

SP - 2945

EP - 2974

BT - Hormones, Brain and Behavior Online

PB - Elsevier Inc.

ER -